Insys Therapeutics Inc (INSY)

11.04
NASDAQ : Health Care
Prev Close 11.04
Day Low/High 0.00 / 0.00
52 Wk Low/High 8.70 / 19.96
Avg Volume 1.10M
Exchange NASDAQ
Shares Outstanding 71.77M
Market Cap 789.47M
EPS 0.80
P/E Ratio 35.48
Div & Yield N.A. (N.A)

Latest News

INSY NOTICE: Rosen Law Firm Reminds Insys Therapeutics, Inc. Investors Of Important Deadline Class Action

INSY NOTICE: Rosen Law Firm Reminds Insys Therapeutics, Inc. Investors Of Important Deadline Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Insys Therapeutics, Inc.

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

First Week of INSY November 17th Options Trading

First Week of INSY November 17th Options Trading

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Insys Therapeutics, Inc. - INSY

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Insys Therapeutics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Insys Therapeutics, Inc. - INSY

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Insys Therapeutics, Inc. - INSY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Insys Therapeutics, Inc.

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Insys Therapeutics, And Advises Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Insys Therapeutics, And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Insys Therapeutics, Inc.

Insys Falls on Earnings Delay

Insys Falls on Earnings Delay

Shares of Insys Therapeutics INSY tumbled Thursday after the company revealed that it would be reporting fourth quarter earnings later than expected thanks to delays from its audit committee.

Insys Therapeutics Announces Delay In The Release Of Its Fourth Quarter And Full Year 2016 Results

Insys Therapeutics Announces Delay In The Release Of Its Fourth Quarter And Full Year 2016 Results

-- Fourth Quarter 2016 Net Sales Estimated at $54 million --

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

5 Earnings Short-Squeeze Plays: Tiffany, Athene and More

These heavily shorted stocks could get squeezed higher if they report positive earnings this week.

Short Interest Drops 14.7% For INSY

Short Interest Drops 14.7% For INSY

The most recent short interest data has been released for the 02/28/2017 settlement date, which shows a 2,019,716 share decrease in total short interest for Insys Therapeutics Inc , to 11,726,537, a decrease of 14.69% since 02/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Insys Therapeutics Shares Cross Above 200 DMA

Insys Therapeutics Shares Cross Above 200 DMA

In trading on Wednesday, shares of Insys Therapeutics Inc crossed above their 200 day moving average of $12.92, changing hands as high as $13.56 per share. Insys Therapeutics Inc shares are currently trading up about 6.7% on the day.

Galena Sacks CEO Amid Escalating Criminal Probe Into Fentanyl Drug Marketing

Galena Sacks CEO Amid Escalating Criminal Probe Into Fentanyl Drug Marketing

The timing of Schwartz' exit is noteworthy given Galena's admission on Jan. 9 of a criminal investigation of the company by the federal prosecutors into the marketing of Abstral.

Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs

Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs

Cannabis stocks are not affected by the volatility in prices during earnings season and instead trade on positive data such as potential FDA approval on their pipeline of drugs.

Interesting INSY Put And Call Options For March 17th

Interesting INSY Put And Call Options For March 17th

Investors in Insys Therapeutics Inc saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 17th contracts and identified one put and one call contract of particular interest.